HROMADKA, Milan, Zuzana MOTOVSKA, Ota HLINOMAZ, Petr KALA, Frantisek TOUSEK, Jiří JARKOVSKÝ, Markéta BERANOVÁ, Pavel JANSKY, Michal SVOBODA, Iveta KŘEPELKOVÁ, Richard ROKYTA, Petr WIDIMSKY a Michal KARPISEK. MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty. JOURNAL OF PERSONALIZED MEDICINE. BASEL: MDPI, 2021, roč. 11, č. 6, s. 1-12. ISSN 2075-4426. Dostupné z: https://dx.doi.org/10.3390/jpm11060508.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty
Autoři HROMADKA, Milan (203 Česká republika), Zuzana MOTOVSKA (203 Česká republika), Ota HLINOMAZ (203 Česká republika, domácí), Petr KALA (203 Česká republika, domácí), Frantisek TOUSEK (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Markéta BERANOVÁ (203 Česká republika, domácí), Pavel JANSKY (203 Česká republika), Michal SVOBODA (203 Česká republika, domácí), Iveta KŘEPELKOVÁ (203 Česká republika), Richard ROKYTA (203 Česká republika), Petr WIDIMSKY (203 Česká republika) a Michal KARPISEK (203 Česká republika).
Vydání JOURNAL OF PERSONALIZED MEDICINE, BASEL, MDPI, 2021, 2075-4426.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30218 General and internal medicine
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 3.508
Kód RIV RIV/00216224:14110/21:00121971
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/jpm11060508
UT WoS 000666506600001
Klíčová slova anglicky acute myocardial infarction; risk stratification; microRNA; miR-126-3P; miR-223-3p; antithrombotic therapy individualization
Štítky 14110115, 14110211, 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 24. 7. 2023 12:58.
Anotace
Aim. This study was designed to evaluate the relationship between microRNAs (miRNAs), miR-126-3p and miR-223-3p, as new biomarkers of platelet activation, and predicting recurrent thrombotic events after acute myocardial infarction (AMI). Methods and Results. The analysis included 598 patients randomized in the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI). The measurements of miRNAs were performed by using a novel miRNA immunoassay method. The association of miRNAs with the occurrence of the ischemic endpoint (EP) (cardiovascular death, nonfatal MI, or stroke) and bleeding were analyzed. The miR-223-3p level was significantly related to an increased risk of occurrence of the ischemic EP within 30 days (odds ratio (OR) = 15.74, 95% confidence interval (CI): 2.07-119.93, p = 0.008) and one year (OR = 3.18, 95% CI: 1.40-7.19, p = 0.006), respectively. The miR-126-3p to miR-223-3p ratio was related to a decreased risk of occurrence of EP within 30 days (OR = 0.14, 95% CI: 0.03-0.61, p = 0.009) and one year (OR = 0.37, 95% CI: 0.17-0.82, p = 0.014), respectively. MiRNAs were identified as independent predictors of EP even after adjustment for confounding clinical predictors. Adding miR-223-3p and miR-126-3p to miR-223-3p ratios as predictors into the model calculating the ischemic risk significantly increased the predictive accuracy for combined ischemic EP within one year more than using only clinical ischemic risk parameters. No associations between miRNAs and bleeding complications were identified. Conclusion. The miR-223-3p and the miR-126-3p are promising independent predictors of thrombotic events and can be used for ischemic risk stratification after AMI.
VytisknoutZobrazeno: 26. 4. 2024 08:09